288 related articles for article (PubMed ID: 26427454)
61. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.
Mercatante DR; Sazani P; Kole R
Curr Cancer Drug Targets; 2001 Nov; 1(3):211-30. PubMed ID: 12188880
[TBL] [Abstract][Full Text] [Related]
62. The phenotypic variability of HK1-associated retinal dystrophy.
Yuan Z; Li B; Xu M; Chang EY; Li H; Yang L; Wu S; Soens ZT; Li Y; Wong LC; Lewis RA; Sui R; Chen R
Sci Rep; 2017 Aug; 7(1):7051. PubMed ID: 28765615
[TBL] [Abstract][Full Text] [Related]
63. Allele-specific antisense oligonucleotides for the treatment of BEST1-related dominantly inherited retinal diseases: An in vitro model.
Karaosmanoglu B; Imren G; Utine E; Taylan Sekeroglu H; Taskiran EZ
Exp Eye Res; 2024 Apr; 241():109833. PubMed ID: 38369231
[TBL] [Abstract][Full Text] [Related]
64. Scaling New Heights in the Genetic Diagnosis of Inherited Retinal Dystrophies.
Gonzàlez-Duarte R; de Castro-Miró M; Tuson M; Ramírez-Castañeda V; Gils RV; Marfany G
Adv Exp Med Biol; 2019; 1185():215-219. PubMed ID: 31884614
[TBL] [Abstract][Full Text] [Related]
65. Antisense oligonucleotides, exon skipping and the dystrophin gene transcript.
Wilton SD; Fletcher S
Acta Myol; 2005 Dec; 24(3):222-9. PubMed ID: 16629057
[TBL] [Abstract][Full Text] [Related]
66. [Specific gene therapy for hereditary retinal dystrophies - an update].
Stieger K; Lorenz B
Klin Monbl Augenheilkd; 2014 Mar; 231(3):210-5. PubMed ID: 24327302
[TBL] [Abstract][Full Text] [Related]
67. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
Jarmin S; Kymalainen H; Popplewell L; Dickson G
Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
[TBL] [Abstract][Full Text] [Related]
68. New approaches to treatment of primary immunodeficiencies: fixing mutations with chemicals.
Hu H; Gatti RA
Curr Opin Allergy Clin Immunol; 2008 Dec; 8(6):540-6. PubMed ID: 18978469
[TBL] [Abstract][Full Text] [Related]
69. The therapeutic potential of antisense-mediated exon skipping.
van Ommen GJ; van Deutekom J; Aartsma-Rus A
Curr Opin Mol Ther; 2008 Apr; 10(2):140-9. PubMed ID: 18386226
[TBL] [Abstract][Full Text] [Related]
70. [Muscular Dystrophies Involving the Retinal Function].
Jägle H
Klin Monbl Augenheilkd; 2016 Mar; 232(3):251-6. PubMed ID: 27011029
[TBL] [Abstract][Full Text] [Related]
71. [Progress in research on pathogenic genes and gene therapy for inherited retinal diseases].
Zhu L; Cao C; Sun J; Gao T; Liang X; Nie Z; Ji Y; Jiang P; Guan M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2017 Feb; 34(1):118-123. PubMed ID: 28186610
[TBL] [Abstract][Full Text] [Related]
72. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy.
Med Lett Drugs Ther; 2018 Mar; 60(1543):53-55. PubMed ID: 29635265
[No Abstract] [Full Text] [Related]
73. Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects.
Rigo F; Seth PP; Bennett CF
Adv Exp Med Biol; 2014; 825():303-52. PubMed ID: 25201110
[TBL] [Abstract][Full Text] [Related]
74. Retinal Hereditary and Degenerative/Dystrophic Diseases (Non-Age-Related Macular Degeneration).
Battaglia Parodi M; La Spina C; Corradetti G; Berchicci L; Petruzzi G; Bandello F
Dev Ophthalmol; 2016; 55():205-11. PubMed ID: 26502105
[TBL] [Abstract][Full Text] [Related]
75. The current status of molecular diagnosis of inherited retinal dystrophies.
Chiang JP; Trzupek K
Curr Opin Ophthalmol; 2015 Jul; 26(5):346-51. PubMed ID: 26214332
[TBL] [Abstract][Full Text] [Related]
76. Molecular Therapies for Inherited Retinal Diseases-Current Standing, Opportunities and Challenges.
Vázquez-Domínguez I; Garanto A; Collin RWJ
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31466352
[TBL] [Abstract][Full Text] [Related]
77. RNA-based therapies in inherited retinal diseases.
Girach A; Audo I; Birch DG; Huckfeldt RM; Lam BL; Leroy BP; Michaelides M; Russell SR; Sallum JMF; Stingl K; Tsang SH; Yang P
Ther Adv Ophthalmol; 2022; 14():25158414221134602. PubMed ID: 36388727
[TBL] [Abstract][Full Text] [Related]
78. RNA modulation, repair and remodeling by splice switching oligonucleotides.
Kole R; Williams T; Cohen L
Acta Biochim Pol; 2004; 51(2):373-8. PubMed ID: 15218534
[TBL] [Abstract][Full Text] [Related]
79. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
80. [Gene therapy for retinal dystrophies].
Charbel Issa P; Groppe M; MacLaren RE
Ophthalmologe; 2012 Feb; 109(2):121-8. PubMed ID: 22350548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
